Zai Lab Ltd (ZLAB)

Zai Lab Ltd stock price live, this page displays NASDAQ ZLAB stock exchange data. View the ZLAB premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Zai Lab Ltd real time stock price chart below.

What Is the Zai Lab Ltd Stock Price Today?
The Zai Lab Ltd stock price today is 28.91.

What Is the Stock Symbol for Zai Lab Ltd?
The stock ticker symbol for Zai Lab Ltd is ZLAB.

Is ZLAB the Same as $ZLAB?
$ZLAB is a common way to refer to the Zai Lab Ltd ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol

What Stock Exchange Does Zai Lab Ltd Trade On?
Zai Lab Ltd is listed and trades on the NASDAQ stock exchange.

Is Zai Lab Ltd a Good Stock to Buy?
Determining whether Zai Lab Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Zai Lab Ltd share price compared with the fair value and other essential metrics.

You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ZLAB quote. (ISIN: US98887Q1040)

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.